All In Biotech

Drug Trial Radar · NCT03997760

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health

Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Oct 21, 2019

Primary completion

Oct 26, 2022

Study completion Oct 26, 2022

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Jun 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants. Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.

Conditions

  • Sickle Cell Disease

Interventions

  • TAK-755Drug

    Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.

  • PlaceboOther

    Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs)Time frame: From date of signing informed consent up to end of study visit (Day 28)
  2. Number of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755Time frame: From date of signing informed consent up to end of study visit (Day 28)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of Colorado Sickle Cell Treatment and Research Center

    Aurora, Colorado

  • Sickle Cell Center

    Denver, Colorado

  • University of Illinois

    Chicago, Illinois

  • Ochsner Health System

    New Orleans, Louisiana

  • Johns Hopkins University School Of Medicine

    Baltimore, Maryland

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • East Carolina University

    Greenville, North Carolina

  • Ohio State University Medical Center

    Columbus, Ohio

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • University of Tennessee -- Memphis

    Memphis, Tennessee

  • VCU Health - Research Parent

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.